1. Immunology and Inflammation
Download icon

Autoimmune Disease: When a virus lies in wait

  1. David Taussig
  2. Yariv Wine  Is a corresponding author
  1. The Shmunis School of Biomedicine and Cancer Research, the George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel
Insight
  • Cited 0
  • Views 641
  • Annotations
Cite this article as: eLife 2021;10:e71121 doi: 10.7554/eLife.71121

Abstract

A mouse model supports the hypothesis that latent Epstein–Barr virus exacerbates the symptoms of rheumatoid arthritis.

Main text

The body’s ability to fight a wide range of external (e.g. viruses, bacteria) and internal (e.g. cancer cells) threats relies on having a fully functional immune system. The immune system can be roughly divided into two parts: the innate system, which is activated quickly and considered the first line of defense; and the adaptive system, which usually ‘kicks in’ a few days following the initial infection and evolves over time to generate a long-lasting and specific response (Murphy et al., 2017).

The power of the adaptive immune system stems from the ability of its white blood cells – T cells and B cells – to express a diverse set of immune receptors that can bind to specific pathogens (Rubelt et al., 2017). As well as having receptors bound to their surface, B cells also secrete some of their receptors in the form of antibodies.

Some B cells, however, produce ‘autoantibodies’ that recognize and bind to molecules on the body’s own cells, causing the immune system to mistakenly attack normal, healthy tissue (Sogkas et al., 2021). There are many mechanisms in place to eliminate these B cells, but if they fail autoimmune disorders can arise (Theofilopoulos et al., 2017). Autoimmune diseases, such as systemic lupus erythematosus multiple sclerosis and rheumatoid arthritis, are thought to be triggered by past viral infections (McClain et al., 2005; Mameli et al., 2012; Costenbader and Karlson, 2006). For example, rheumatoid arthritis (RA) – an inflammatory autoimmune disease that affects the joints – has been associated with Epstein-Barr virus (EBV) infection (Guo et al., 2018; Costenbader and Karlson, 2006).

Most exposures to EBV occur during childhood or adolescence without leading to RA, but the disease tends to appear after patients turn 60. Thus, it is hypothesized that EBV latency – a situation in which the virus becomes dormant within the host cell without producing more viruses – may contribute to RA symptoms appearing later in life. This is in agreement with a previous study in which mice with an autoimmune condition called experimental autoimmune encephalopathy were latently infected with a homolog of EBV called gammaherpesvirus 68 (γHV68). The infection exacerbated the autoimmune condition without changing autoantibody levels, and led to a disease that resembles multiple sclerosis (Casiraghi et al., 2012). But it is unclear whether EBV has the same effect on RA.

Now, in eLife, Marc Horwitz and colleagues from the University of British Columbia – including Isobel Mouat as first author – report that latent viral infection also worsens the symptoms of a mouse model for RA (Mouat et al., 2021). They used a mouse model for RA that suffers from an autoimmune condition called type II collagen-induced arthritis (CIA). When these mice are exposed to type II collagen, they develop arthritis with a sustained T cell response and as a result produce anti-collagen autoantibodies that can infiltrate the joints (Inglis et al., 2007).

Mouat et al. infected CIA mice with latent γHV68 to develop a mouse model that can shed light on how EBV may affect the symptoms of RA in humans. The experiments showed that infection increased the clinical parameters used to measure the severity of CIA (Figure 1), demonstrating the negative impact of the latent virus. Specifically, a subset of B cells called age-associated B cells were shown to be expressed in significantly higher proportions than in uninfected mice. Finally, Mouat et al. used a strain of γHV68 that cannot become latent to show that latency is necessary for the virus to exacerbate CIA.

Parameters measured to determine CIA severity.

Top: Mice were infected with latent γHV68 and treated with type II collagen to model the effects of Epstein-Barr virus on rheumatoid arthritis. This manipulation causes the symptoms of type II collagen arthritis (CIA) to become more severe and increase inflammation in the mice’s joints. Bottom: the parameters measured to assess the severity of the autoimmune disease include (circle, clockwise from top left): the levels of the cytokine IFNγ in the spleen (which increased in the CIA mice infected with γHV68); the proportions of different T cell populations (which became similar to what is observed during infections); the phenotypes of B cells in the spleen (more age-associated B cells were observed); and the time until onset of the disease (which decreased). Created with BioRender.com.

Mouat et al. show that latent γHV68 infection in mice clearly alters autoimmune disease onset and severity, potentially reflecting how latent EBV infection affects RA in humans. Future research will be needed to reveal exactly how B cells are impacted by EBV. Notably, the development and validation of the RA model in mice will facilitate future studies aiming to better understand the nature of the relationship between EBV infection and RA.

References

  1. Book
    1. Murphy K
    2. Weaver C
    3. Janeway C
    (2017)
    Janeway's Immunobiology
    Garland Science.

Article and author information

Author details

  1. David Taussig

    David Taussig is in the Shmunis School of Biomedicine and Cancer Research, the George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6653-7308
  2. Yariv Wine

    Yariv Wine is in the Shmunis School of Biomedicine and Cancer Research, the George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

    For correspondence
    yarivwine@tauex.tau.ac.il
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5767-9059

Publication history

  1. Version of Record published: August 4, 2021 (version 1)

Copyright

© 2021, Taussig and Wine

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 641
    Page views
  • 60
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Immunology and Inflammation
    Anders Laustsen et al.
    Tools and Resources Updated

    Plasmacytoid dendritic cells (pDCs) constitute a rare type of immune cell with multifaceted functions, but their potential use as a cell-based immunotherapy is challenged by the scarce cell numbers that can be extracted from blood. Here, we systematically investigate culture parameters for generating pDCs from hematopoietic stem and progenitor cells (HSPCs). Using optimized conditions combined with implementation of HSPC pre-expansion, we generate an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord blood-derived HSPCs. Furthermore, we demonstrate that such protocol allows HSPC-pDC generation from whole-blood HSPCs, and these cells display a pDC phenotype and function. Using GMP-compliant medium, we observe a remarkable loss of TLR7/9 responses, which is rescued by ascorbic acid supplementation. Ascorbic acid induces transcriptional signatures associated with pDC-specific innate immune pathways, suggesting an undescribed role of ascorbic acid for pDC functionality. This constitutes the first protocol for generating pDCs from whole blood and lays the foundation for investigating HSPC-pDCs for cell-based immunotherapy.

    1. Cell Biology
    2. Immunology and Inflammation
    Janine JG Arts et al.
    Research Article Updated

    Upon inflammation, leukocytes rapidly transmigrate across the endothelium to enter the inflamed tissue. Evidence accumulates that leukocytes use preferred exit sites, alhough it is not yet clear how these hotspots in the endothelium are defined and how they are recognized by the leukocyte. Using lattice light sheet microscopy, we discovered that leukocytes prefer endothelial membrane protrusions at cell junctions for transmigration. Phenotypically, these junctional membrane protrusions are present in an asymmetric manner, meaning that one endothelial cell shows the protrusion and the adjacent one does not. Consequently, leukocytes cross the junction by migrating underneath the protruding endothelial cell. These protrusions depend on Rac1 activity and by using a photo-activatable Rac1 probe, we could artificially generate local exit-sites for leukocytes. Overall, we have discovered a new mechanism that uses local induced junctional membrane protrusions to facilitate/steer the leukocyte escape/exit from inflamed vessel walls.